Head & Neck Cancers

Expert Lori Wirth, MD, highlights key points from a second real-world patient scenario of radioiodine-refractory differentiated thyroid cancer.

Pembrolizumab with or without chemotherapy resulted in a numerically longer overall survival benefit vs cetuximab plus chemotherapy in patients with head and neck squamous cell carcinoma and a PD-L1 combined positive score (CPS) between 1 and 19, but did not improve survival in the subset with a PD-L1 CPS of less than 1.

The European Commission has approved the use of cabozantinib for use as a single agent in adult patients with locally advanced or metastatic differentiated thyroid carcinoma who are refractory or not eligible to receive radioactive iodine and who have progressed during or following previous systemic treatment.

The FDA is seeking the approval of toripalimab plus gemcitabine and cisplatin in the frontline treatment of patients with advanced recurrent or metastatic nasopharyngeal carcinoma and for use as a monotherapy in the second-line and later treatment of those with recurrent or metastatic disease.

Expert advice on addressing adverse events, particularly through dose holds or reduction, in patients on lenvatinib therapy for radioiodine-refractory DTC.

Shared insight on selecting appropriate patients for lenvatinib therapy in differentiated thyroid cancer, as well as optimizing dosing strategies in the context of clinical trial data.

A brief discussion on where endocrinologists and oncologists respectively fit into the differentiated thyroid cancer treatment paradigm.

Reflecting on the first patient scenario of radioiodine-refractory DTC, experts share their considerations for optimally selecting and sequencing therapy in this setting.

The combination of tislelizumab and gemcitabine/cisplatin continued to demonstrate a greater progression-free survival benefit than chemotherapy alone when used in the frontline treatment of patients with recurrent or metastatic nasopharyngeal cancer.

Marcia S. Brose, MD, PhD, FASCO, and a panel of thyroid cancer experts share their insights into the evolving treatment landscape, including the use of VEGF receptor inhibitors and some of the precision medicine treatments now identified for molecularly selected subsets of patients with differentiated thyroid cancer, such as BRAF, RET, and TRK inhibitors.

Perspectives on the use of lenvatinib therapy to manage a patient with radioiodine-refractory DTC, preceding broader considerations for sequencing kinase inhibitor therapy.

Expert Marcia Brose, MD, details a clinical scenario wherein a patient is diagnosed with differentiated thyroid cancer and managed with surgical and radiotherapy.

The combination of pepinemab and pembrolizumab elicited encouraging responses and tolerability as frontline therapy in patients with recurrent or metastatic head and neck cancer.

The addition of ramucirumab to pembrolizumab elicited an encouraging response rate when used in the frontline treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma.

The combination of pembrolizumab and pepinemab showcased encouraging safety and tolerability when given as first-line treatment in patients with advanced, recurrent, or metastatic head and neck squamous cell carcinoma.

The FDA has accepted an investigational new drug application for the photoimmunotherapy treatment, RM-1995, for patients with advanced cutaneous squamous cell carcinoma or head and neck squamous cell carcinoma.

Marshall Posner, MD, shares his clinical experience with the use of tipifarnib in patients with head and neck cancer whose tumors harbor HRAS mutations.

Lori J. Wirth, MD, discusses the utility of tipifarnib in patients with head and neck cancer whose tumors harbor HRAS mutations.

The investigational monoclonal antibody enoblituzumab has demonstrated activity in preclinical studies and in combination with pembrolizumab in phase 1/2 studies in patients with checkpoint inhibitor–naïve head and neck squamous cell carcinoma and non–small cell lung cancer.

A personalized treatment paradigm based on hypoxia imaging is promising and may yield a successful, personalized de-escalation strategy for patients with HPV-associated oropharynx cancer.

The Cancer Cell Map Initiative, developed by investigators at the University of California San Francisco and the University of California San Diego, has successfully charted how hundreds of genetic mutations involved in breast cancer and cancers of the head and neck affect the activity of proteins that ultimately lead to disease.

Glenn J. Hanna, MD, discusses promising data reported with tipifarnib in patients with HRAS-mutated head and neck cancer.

Glenn J. Hanna, MD, discusses the role of second-line cetuximab (Erbitux) in head and neck cancer.

The FDA has accepted for review a biologics license application for the use of toripalimab in combination with gemcitabine and cisplatin in the frontline treatment of patients with advanced recurrent or metastatic nasopharyngeal carcinoma, and for use as a single agent in the second- or later-line treatment of patients with recurrent or metastatic nasopharyngeal carcinoma following platinum-containing chemotherapy.

The clinical-stage immunotherapy company PDS Biotechnology Corporation has announced the temporary suspension of recruitment to the National Cancer Institute–led phase 2 trial, which is evaluating a novel triplet combination comprised of PDS0101 and 2 immunomodulating agents in patients with advanced human papillomavirus cancers.